On September 13, 2022 The Swedish scale-up company Genagon Therapeutics, together with Mosaique Diagnostics, reported that it receive 7 MSEK in funding from Eurostars for the continued development of biological treatment for triple negative breast cancer (Press release, Genagon Therapeutics, SEP 13, 2022, View Source;utm_medium=rss&utm_campaign=genagon-receive-eurostars-grant-funding [SID1234619530]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The consortium partners aim to jointly undertake major steps towards the transition from the preclinical to clinical development of GEN209 – a drug candidate for triple-negative breast cancer (TNBC). This will be a first-in-class monoclonal antibody-drug conjugate (ADC) targeting Clptm1, a novel molecular target expressed in solid tumors.

"This is very positive, and we are happy for this. This will help us secure in vivo efficacy data, identify biomarkers for patient selection and treatment outcome follow-up. We will also design regulatory and toxicology programs allowing for a successful transition to clinical trials", says Moa Fransson, CEO at Genagon Therapeutics.